{
  "id": "ded381bf1b583da5",
  "title": "Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing",
  "description": "Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg\u2019s Katie Greifeld to discuss GLP-1 supply, pricing and the company\u2019s lawsuit against Hims over alleged obesity drug copycats. (Source: Bloomberg)",
  "content": "Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg\u2019s Katie Greifeld to discuss GLP-1 supply, pricing and the company\u2019s lawsuit against Hims over alleged obesity drug copycats. (Source: Bloomberg)",
  "source": "Bloomberg Markets",
  "source_url": "https://www.bloomberg.com/news/videos/2026-02-11/novo-nordisk-ceo-on-hims-suit-wegovy-demand-and-pricing-video",
  "published_at": "2026-02-11T21:03:02+00:00",
  "fetched_at": "2026-02-12T00:28:38.246764+00:00",
  "category": "macroeconomics_finance",
  "subcategory": null,
  "keywords": [
    "ai",
    "drug"
  ],
  "location": null,
  "raw_data": {
    "title": "Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing",
    "description": "Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg\u2019s Katie Greifeld to discuss GLP-1 supply, pricing and the company\u2019s lawsuit against Hims over alleged obesity drug copycats. (Source: Bloomberg)",
    "url": "https://www.bloomberg.com/news/videos/2026-02-11/novo-nordisk-ceo-on-hims-suit-wegovy-demand-and-pricing-video",
    "published": "2026-02-11T21:03:02+00:00",
    "source": "Bloomberg Markets"
  }
}